Dr. Tahir Latif, MD

Dr. Latif practices at UC Medical Center in Cincinnati, Ohio.

Dr. Latif's NPI, 1750378717, was assigned on October 4, 2005. Dr. Latif holds Ohio license 35 094776.

Dr. Latif's primary practice is UC Medical Center, at 3188 Bellevue Ave, Cincinnati, OH 45219 in Hamilton County. The practice phone is (513) 584-1000.

Dr. Latif's primary practice is UC Medical Center in Cincinnati, Ohio. Dr. Latif is also affiliated with University of Cincinnati Medical Center. The medical group on file is University of Cincinnati Physicians. Dmand AI also links Dr. Latif to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Latif practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Latif's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Latif's licenses on file in 2 states: Ohio and New Mexico.

CMS data shows 1,040 Medicare services from Dr. Latif across 9 procedure codes in 2024, for 277 Medicare patients. Medicare paid $76,965 for them.

CMS counts 277 Medicare patients who saw Dr. Latif in 2024. The largest group is 65 to 74, with 129 patients. 74% of them have high blood pressure, and 69% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Latif's median patient age at 66, with 44% women.

In 2024, Dr. Latif wrote 663 Medicare Part D claims for 120 patients. 53% of them were for generic drugs. CMS names the drug for 487 of them, across 17 drugs with 11 or more claims each, at $4,908,132 in total drug cost. In 2023, CMS named 290 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Latif for performance year 2024, reported as part of a group. Dr. Latif accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Latif, published from 2012 to 2023. 2014 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, COVID-19 and Neoadjuvant Therapy. Dr. Latif has published most often in Blood Adv. Dr. Latif's most frequent co-authors are Jordan Raed Kharofa, MD, Olugbenga Olanrele Olowokure, MD and Syed Arif Ahmad, MD.

Dmand AI links Dr. Latif to 10 clinical trials, 7 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Mantle-Cell. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 43 general payments to Dr. Latif from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 91% of the total. Amgen Inc. paid the most, $24,528. It also lists 1 research payment totaling $7,371 in 2019.